This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Inspire Medical Stock Falls Despite Solid Preliminary Q4 Revenues
by Zacks Equity Research
INSP's revenue growth in the fourth quarter is likely to have been boosted by increased market penetration in existing centers and expansion into new implanting centers.
Why Inspire Medical Systems (INSP) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ensign Group Bolsters Healthcare Portfolio With Nine New Facilities
by Zacks Equity Research
ENSG acquires operations of nine skilled nursing facilities, marking its debut in Alabama and strengthening its Tennessee footprint, to enhance care and grow its Skilled Services segment.
Here's Why Encompass Health is a Smart Addition to Your Portfolio
by Zacks Equity Research
EHC is well-poised for growth on the back of robust demand for effective inpatient rehabilitation services, frequent expansion initiatives and solid cash reserves.
Azenta (AZTA) Surges 7.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Azenta (AZTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
The Zacks Analyst Blog Highlights Inspire Medical, Omnicell, Talkspace, Butterfly Network and Clover Health
by Zacks Equity Research
Inspire Medical, Omnicell, Talkspace, Butterfly Network and Clover Health are included in this Analyst Blog.
Inspire (INSP) Down 3.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 Medical Info System Stocks to Buy for a Stable Portfolio in 2025
by Nalak Das
Five medical info systems stocks have strong potential for 2025. These are: INSP, OMCL, TALK, BFLY, CLOV.
5 Growth Stocks to Buy in December for Impressive Short-Term Upside
by Nalak Das
These five growth stocks have strong potential for December. These are: MNDY, PSN, PI, INSP, INGR.
Encompass Health Up 60% in a Year: What Lies Ahead for Investors?
by Zacks Equity Research
EHC remains well-poised for growth on the back of solid discharge growth, an aging U.S. population, frequent expansion initiatives and strong cash reserves.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
INSP Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the third quarter.
Here's What Key Metrics Tell Us About Inspire (INSP) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for Inspire (INSP) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Inspire Medical Systems (INSP) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 900% and 2.81%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
HIMS Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
by Zacks Equity Research
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the third quarter.
Seeking Clues to Inspire (INSP) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Inspire (INSP) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zacks Industry Outlook Medical Systems, 10x Genomics and Omnicell
by Zacks Equity Research
Medical Systems, 10x Genomics and Omnicell have been highlighted in this Industry Outlook article.
3 Medical Info Systems Stocks to Gain From Healthcare Digitization
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Inspire Medical Systems, 10x Genomics and Omnicell are expected to gain from the GenAI wave.
Inspire (INSP) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Inspire (INSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CAH Stock May Gain Following the Distribution Deal With T2 Biosystems
by Zacks Equity Research
Cardinal Health and T2 Biosystems announce an agreement selecting the former to sell direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens.
Integer Holdings (ITGR) Gains 30.5% YTD: What's Driving the Stock?
by Zacks Equity Research
Integer Holdings (ITGR) shares gain on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.
PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer
by Zacks Equity Research
PROCEPT BioRobotics receives FDA's approval to begin a pivotal randomized clinical study to assess the use of Aquablation therapy in treating prostate cancer patients.